Skip to content

Trial Summary

A Phase 1, First-in-Human, Open-label, Single-Arm study of SUPLEXA™ therapy in Patients with Metastatic Solid Tumors and Haematologic Malignancies

Acronym:

SUPLEXA-101

ACTRN/NCT /ethics:

 

Scientific title:

A Phase 1, First-in-Human, Open-label, Single-Arm study of SUPLEXA™ therapy in Patients with Metastatic Solid Tumors and Haematologic Malignancies

Sponsor / Cooperative group:

 

Trial & Patient Characteristics

Cancer TypeAll cancers
Trial TypeTreatment
PhasePhase I
Age Range-
Sex-
Tumour Stream -
Cancer StageMetastatic or Widespread
Anticipated Start Date-
Anticipated End Date-

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Francis Parnis
Recruitment StatusIn start-up